Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Ribociclib|DRUG: Letrozole or Anastrozole|DRUG: Goserelin
Sponsor: Novartis Pharmaceuticals